"Forty-Third Medical Associates Absolute Clinical Research"
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beach, James L
EAGLE-2, NCT04020341 / 2018-001801-98: A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

Checkmark Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.
Recruiting
3
2500
Europe, US, RoW
Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
GlaxoSmithKline
Urinary Tract Infections
03/24
03/24
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Checkmark Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity.
Checkmark Multimodal Circulating Tumor DNA (ctDNA) Blood-Based Colorectal Cancer (CRC) Screening Test Demonstrates Clinically Meaningful Sensitivity Across Multiple Clinical Parameters
Recruiting
N/A
20000
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
11/22
01/24
Rodriguez, Lucia
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Recruiting
3
420
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
09/22
10/22
NCT04828707: Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

Recruiting
N/A
300
US
Nerivio active device, Nerivio sham device
Theranica
Migraine
08/22
09/22
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Checkmark Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity.
Checkmark Multimodal Circulating Tumor DNA (ctDNA) Blood-Based Colorectal Cancer (CRC) Screening Test Demonstrates Clinically Meaningful Sensitivity Across Multiple Clinical Parameters
Recruiting
N/A
20000
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
11/22
01/24

Download Options